Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin. Part 1: Experimental studies

Science Translational Medicine

Volumn 2, Issue 59, 2010, Pages

  Ferrandi, Mara ^a   Molinari, Isabella ^a   Torielli, Lucia ^a   Padoani, Gloria ^a   Salardi, Sergio ^a   Rastaldi, Maria Pia ^b   Ferrari, Patrizia ^a   Bianchi, Giuseppe ^a,c  

^a Prassis Sigma Tau Research Institute   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA ADDUCIN; OUABAIN; PROTEIN SH2; ROSTAFUROXIN; 17 (3 FURYL) 5BETA ANDROSTANE 3,14,17 TRIOL; 17-(3-FURYL)-5BETA-ANDROSTANE-3,14,17-TRIOL; ADDUCIN; ANDROSTANE DERIVATIVE; ANTIHYPERTENSIVE AGENT; CALMODULIN BINDING PROTEIN; MUTANT PROTEIN; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HYPERTENSION; MALE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; WILD TYPE; ANIMAL; BLOOD PRESSURE; CELL FREE SYSTEM; CELL LINE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SRC HOMOLOGY DOMAIN;

ANDROSTANOLS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALMODULIN-BINDING PROTEINS; CELL LINE; CELL-FREE SYSTEM; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KIDNEY; MALE; MUTANT PROTEINS; OUABAIN; PROTEIN BINDING; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE; SRC HOMOLOGY DOMAINS; SRC-FAMILY KINASES; TRANSFECTION;

EID: 78649416474     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001815     Document Type: Article

References (58)

1. B. Williams, The year in hypertension. J. Am. Coll. Cardiol. 48, 1698-1711 (2006).
2. T. A. Gaziano, A. Bitton, S. Anand, M. C. Weinstein; International Society of Hypertension, The global cost of nonoptimal blood pressure. J. Hypertens. 27, 1472-1477 (2009).
3. A. V. Chobanian, Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N. Engl. J. Med. 361, 878-887 (2009).
4. D. Levy, G. B. Ehret, K. Rice, G. C. Verwoert, L. J. Launer, A. Dehghan, N. L. Glazer, A. C. Morrison, A. D. Johnson, T. Aspelund, Y. Aulchenko, T. Lumley, A. Köttgen, R. S. Vasan, F. Rivadeneira, G. Eiriksdottir, X. Guo, D. E. Arking, G. F. Mitchell, F. U. Mattace-Raso, A. V. Smith, K. Taylor, R. B. Scharpf, S. J. Hwang, E. J. Sijbrands, J. Bis, T. B. Harris, S. K. Ganesh, C. J. O'Donnell, A. Hofman, J. I. Rotter, J. Coresh, E. J. Benjamin, A. G. Uitterlinden, G. Heiss, C. S. Fox, J. C. Witteman, E. Boerwinkle, T. J. Wang, V. Gudnason, M. G. Larson, A. Chakravarti, B. M. Psaty, C. M. van Duijn, Genome-wide association study of blood pressure and hypertension. Nat. Genet. 41, 677-687 (2009).
5. C. Newton-Cheh, T. Johnson, V. Gateva, M. D. Tobin, M. Bochud, L. Coin, S. S. Najjar, J. H. Zhao, S. C. Heath, S. Eyheramendy, K. Papadakis, B. F. Voight, L. J. Scott, F. Zhang, M. Farrall, T. Tanaka, C. Wallace, J. C. Chambers, K. T. Khaw, P. Nilsson, P. van der Harst, S. Polidoro, D. E. Grobbee, N. C. Onland-Moret, M. L. Bots, L. V. Wain, K. S. Elliott, A. Teumer, J. Luan, G. Lucas, J. Kuusisto, P. R. Burton, D. Hadley, W. L. McArdle; Wellcome Trust Case Control Consortium, M. Brown, A. Dominiczak, S. J. Newhouse, N. J. Samani, J. Webster, E. Zeggini, J. S. Beckmann, S. Bergmann, N. Lim, K. Song, P. Vollenweider, G. Waeber, D. M. Waterworth, X. Yuan, L. Groop, M. Orho-Melander, A. Allione, A. Di Gregorio, S. Guarrera, S. Panico, F. Ricceri, V. Romanazzi, C. Sacerdote, P. Vineis, I. Barroso, M. S. Sandhu, R. N. Luben, G. J. Crawford, P. Jousilahti, M. Perola, M. Boehnke, L. L. Bonnycastle, F. S. Collins, A. U. Jackson, K. L. Mohlke, H. M. Stringham, T. T. Valle, C. J. Willer, R. N. Bergman, M. A. Morken, A. Döring, C. Gieger, T. Illig, T. Meitinger, E. Org, A. Pfeufer, H. E. Wichmann, S. Kathiresan, J. Marrugat, C. J. O'Donnell, S. M. Schwartz, D. S. Siscovick, I. Subirana, N. B. Freimer, A. L. Hartikainen, M. I. McCarthy, P. F. O'Reilly, L. Peltonen, A. Pouta, P. E. de Jong, H. Snieder, W. H. van Gilst, R. Clarke, A. Goel, A. Hamsten, J. F. Peden, U. Seedorf, A. C. Syvänen, G. Tognoni, E. G. Lakatta, S. Sanna, P. Scheet, D. Schlessinger, A. Scuteri, M. Dörr, F. Ernst, S. B. Felix, G. Homuth, R. Lorbeer, T. Reffelmann, R. Rettig, U. Völker, P. Galan, I. G. Gut, S. Hercberg, G. M. Lathrop, D. Zelenika, P. Deloukas, N. Soranzo, F. M. Williams, G. Zhai, V. Salomaa, M. Laakso, R. Elosua, N.G. Forouhi,H. Völzke, C. S. Uiterwaal, Y.T. van der Schouw, M. E. Numans, G. Matullo, G.Navis, G.Berglund, S. A. Bingham, J. S. Kooner, J. M. Connell, S. Bandinelli, L. Ferrucci, H. Watkins, T. D. Spector, J. Tuomilehto, D. Altshuler, D. P. Strachan, M. Laan, P. Meneton, N. J. Wareham, M. Uda, M. R. Jarvelin, V. Mooser, O. Melander, R. J. Loos, P. Elliott, G. R. Abecasis, M. Caulfield, P. B. Munroe, Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 41, 666-676 (2009).
6. Y. Wang, J. R. O'Connell, P. F. McArdle, J. B. Wade, S. E. Dorff, S. J. Shah, X. Shi, L. Pan, E. Rampersaud, H. Shen, J. D. Kim, A. R. Subramanya, N. I. Steinle, A. Parsa, C. C. Ober, P. A. Welling, A. Chakravarti, A. B. Weder, R. S. Cooper, B. D. Mitchell, A. R. Shuldiner, Y. P. Chang, Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc. Natl. Acad. Sci. U.S.A. 106, 226-231 (2009).
7. A. W. Cowley Jr., The genetic dissection of essential hypertension. Nat. Rev. Genet. 7, 829-840 (2006).
8. K. Fitzgerald, RNAi versus small molecules: Different mechanisms and specificities can lead to different outcomes. Curr. Opin. Drug Discov. Devel. 8, 557-566 (2005).
9. W. A. Weiss, S. S. Taylor, K. M. Shokat, Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol. 3, 739-744 (2007).
10. M. Visintin, T. Melchionna, I. Cannistraci, A. Cattaneo, In vivo selection of intrabodies specifically targeting protein-protein interactions: A general platform for an "undruggable" class of disease targets. J. Biotechnol. 135, 1-15 (2008).
11. G. Bianchi, Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: From gene polymorphism to clinical symptoms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, R1536-R1549 (2005).
12. G. Bianchi, G. Tripodi, G. Casari, S. Salardi, B. R. Barber, R. Garcia, P. Leoni, L. Torielli, D. Cusi, M. Ferrandi, L. A. Pinna, F. E. Baralle, P. Ferrari, Two point mutations within the adducin genes are involved in blood pressure variation. Proc. Natl. Acad. Sci. U.S.A. 91, 3999-4003 (1994).
13. G. Tripodi, F. Valtorta, L. Torielli, E. Chieregatti, S. Salardi, L. Trusolino, A. Menegon, P. Ferrari, P. C. Marchisio, G. Bianchi, Hypertension-associated point mutations in the adducin α and β subunits affect actin cytoskeleton and ion transport. J. Clin. Invest. 97, 2815-2822 (1996).
14. D. Cusi, C. Barlassina, T. Azzani, G. Casari, L. Citterio, M. Devoto, N. Glorioso, C. Lanzani, P. Manunta, M. Righetti, R. Rivera, P. Stella, C. Troffa, L. Zagato, G. Bianchi, Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 349, 1353-1357 (1997).
15. M. Ferrandi, I. Molinari, P. Barassi, E. Minotti, G. Bianchi, P. Ferrari, Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J. Biol. Chem. 279, 33306-33314 (2004).
16. P. Manunta, M. Ferrandi, G. Bianchi, J. M. Hamlyn, Endogenous ouabain in cardiovascular function and disease. J. Hypertens. 27, 9-18 (2009).
17. Y. Matsuoka, X. Li, V. Bennett, Adducin: Structure, function and regulation. Cell. Mol. Life Sci. 57, 884-895 (2000).
18. C. A. Hughes, V. Bennett, Adducin: A physical model with implications for function in assembly of spectrin-actin complexes. J. Biol. Chem. 270, 18990-18996 (1995).
19. A. Aderem, The MARCKS brothers: A family of protein kinase C substrates. Cell 71, 713-716 (1992).
20. Y. Fukata, N. Oshiro, N. Kinoshita, Y. Kawano, Y. Matsuoka, V. Bennett, Y. Matsuura, K. Kaibuchi, Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J. Cell Biol. 145, 347-361 (1999).
21. +) ATPase associated with essential hypertension. Nature 300, 650-652 (1982).
22. M. Ferrandi, P. Manunta, S. Balzan, J. M. Hamlyn, G. Bianchi, P. Ferrari, Ouabain-like factor quantification in mammalian tissues and plasma: Comparison of two independent assays. Hypertension 30, 886-896 (1997).
23. +-ATPase. J. Biol. Chem. 275, 27832-27837 (2000).
24. 2+ concentrations. J. Biol. Chem. 275, 27838-27844 (2000).
25. P. Ferrari, L. Torielli, M. Ferrandi, G. Padoani, L. Duzzi, M. Florio, F. Conti, P. Melloni, L. Vesci, N. Corsico, G. Bianchi, PST2238: A new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J. Pharmacol. Exp. Ther. 285, 83-94 (1998).
26. +-ATPase alterations in ouabain and adducin-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R529-R535 (2006).
27. P. Ferrari, M. Ferrandi, G. Tripodi, L. Torielli, G. Padoani, E. Minotti, P. Melloni, G. Bianchi, PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J. Pharmacol. Exp. Ther. 288, 1074-1083 (1999).
28. C. Lanzani, L. Citterio, N. Glorioso, P. Manunta, G. Tripodi, E. Salvi, S. D. Carpini, M. Ferrandi, E. Messaggio, J. A. Staessen, D. Cusi, F. Macciardi, G. Argiolas, G. Valentini, P. Ferrari, G. Bianchi, Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin. Part 2: Clinical studies. Sci. Transl. Med. 2, 59ra87 (2010).
29. G. Tripodi, M. Florio, M. Ferrandi, R. Modica, H. Zimdahl, N. Hubner, P. Ferrari, G. Bianchi, Effect of Add1 gene transfer on blood pressure in reciprocal congenic strains of Milan rats. Biochem. Biophys. Res. Commun. 324, 562-568 (2004).
30. L. Torielli, S. Tivodar, R. C. Montella, R. Iacone, G. Padoani, P. Tarsini, O. Russo, D. Sarnataro, P. Strazzullo, P. Ferrari, G. Bianchi, C. Zurzolo, α-Adducin mutations increase Na/K pump activity in renal cells by affecting constitutive endocytosis: Implications for tubular Na reabsorption. Am. J. Physiol. Renal Physiol. 295, F478-F487 (2008).
31. +-ATPase trafficking in response to GPCR signals and intracellular sodium. Circ. Res. 95, 1100-1108 (2004).
32. D. Yarar, C. M. Waterman-Storer, S. L. Schmid, A dynamic actin cytoskeleton functions at multiple stages of clathrin-mediated endocytosis. Mol. Biol. Cell 16, 964-975 (2005).
33. J. Y. Kim, Y. G. Lee, M. Y. Kim, S. E. Byeon, M. H. Rhee, J. Park, D. R. Katz, B. M. Chain, J. Y. Cho, Src-mediated regulation of inflammatory responses by actin polymerization. Biochem. Pharmacol. 79, 431-443 (2010).
34. +-ATPase forms a functional signaling complex. Mol. Biol. Cell 17, 317-326 (2006).
35. M. Joëls, Corticosteroid effects in the brain: U-shape it. Trends Pharmacol. Sci. 27, 244-250 (2006).
36. H. P. Gaeggeler, E. Gonzalez-Rodriguez, N. F. Jaeger, D. Loffing-Cueni, R. Norregaard, J. Loffing, J. D. Horisberger, B. C. Rossier, Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosterone-stimulated sodium transport in a novel renal cell line. J. Am. Soc. Nephrol. 16, 878-891 (2005).
37. A. A. Banday, M. F. Lokhandwala, Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-nitric oxide signaling. Hypertension 52, 1099-1105 (2008).
38. J. Tian, X. Li, M. Liang, L. Liu, J. X. Xie, Q. Ye, P. Kometiani, M. Tillekeratne, R. Jin, Z. Xie, Changes in sodium pump expression dictate the effects of ouabain on cell growth. J. Biol. Chem. 284, 14921-14929 (2009).
39. T. Gilmer, M. Rodriguez, S. Jordan, R. Crosby, K. Alligood, M. Green, M. Kimery, C. Wagner, D. Kinder, P. Charifson, A. M. Hassell, D. Willard, M. Luther, D. Rusnak, D. D. Sternbach, M. Mehrotra, M. Peel, L. Shampine, R. Davis, J. Robbins, I. R. Patel, D. Kassel, W. Burkhart, M. Moyer, T. Bradshaw, J. Berman, Peptide inhibitors of src SH3-SH2-phosphoprotein interactions. J. Biol. Chem. 269, 31711-31719 (1994).
40. +-ATPase as a signal transducer. Eur. J. Biochem. 269, 2434-2439 (2002).
41. L. D. Bozulic, W. L. Dean, N. A. Delamere, The influence of Src-family tyrosine kinases on Na,K-ATPase activity in lens epithelium. Invest. Ophthalmol. Vis. Sci. 46, 618-622 (2005).
42. K. A. Holthouser, A. Mandal, M. L. Merchant, J. R. Schelling, N. A. Delamere, R. R. Valdes Jr., S. C. Tyagi, E. D. Lederer, S. J. Khundmiri, Ouabain stimulates Na-K-ATPase through a sodium/hydrogen exchanger-1 (NHE-1)-dependent mechanism in human kidney proximal tubule cells. Am. J. Physiol. Renal Physiol. 299, F77-F90 (2010).
43. W. Schoner, G. Scheiner-Bobis, Endogenous and exogenous cardiac glycosides: Their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 293, C509-C536 (2007).
44. J. Gao, R. S. Wymore, Y. Wang, G. R. Gaudette, I. B. Krukenkamp, I. S. Cohen, R. T. Mathias, Isoform-specific stimulation of cardiac Na/K pumps by nanomolar concentrations of glycosides. J. Gen. Physiol. 119, 297-312 (2002).
45. A. Miyakawa-Naito, P. Uhlén, M. Lal, O. Aizman, K. Mikoshiba, H. Brismar, S. Zelenin, A. Aperia, Cell signaling microdomain with Na,K-ATPase and inositol 1,4,5-trisphosphate receptor generates calcium oscillations. J. Biol. Chem. 278, 50355-50361 (2003).
46. X. Liu, Z. Spicarová, S. Rydholm, J. Li, H. Brismar, A. Aperia, Ankyrin B modulates the function of Na,K-ATPase/inositol 1,4,5-trisphosphate receptor signaling microdomain. J. Biol. Chem. 283, 11461-11468 (2008).
47. +-ATPase to ERK1/2. J. Biol. Chem. 276, 42050-42056 (2001).
48. +-ATPase to ERK1/2. J. Cardiovasc. Pharmacol. 41, 609-614 (2003).
49. i in rat cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 281, H1899-H1907 (2001).
50. J. Heineke, J. D. Molkentin, Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589-600 (2006).
51. J. A. Engelman, J. Luo, L. C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619 (2006).
52. ATP channels. Mol. Cell. Biochem. 242, 181-187 (2003).
53. +-ATPase to hypertrophy and its marker genes in cardiac myocytes. J. Biol. Chem. 274, 19323-19328 (1999).
54. +-ATPase: Relation to genetic hypertension. Am. J. Physiol. Heart Circ. Physiol. 277, H1338-H1349 (1999).
55. +-ATPase relaxes cell attachment and sends a specific signal (NACos) to the nucleus. J. Membr. Biol. 198, 147-158 (2004).
56. +-ATPase and cell attachment. J. Cell Sci. 112, 4223-4232 (1999).
57. A. J. Muslin, MAPK signalling in cardiovascular health and disease: Molecular mechanisms and therapeutic targets. Clin. Sci. 115, 203-218 (2008).
58. Acknowledgments: We thank E. Minotti and C. Camisasca for rat treatments; S. Pastore for recombinant adducin preparations; S. Rodighiero for confocal microscopy analysis; S. Karlish for anti-γ Na,K-ATPase antibody; Z. Xie for GST-Src kinase domain construct; and C. Scotti for technical assistance. Author contributions: M.F. and I.M. performed experimental work in rats and cell-free systems; L.T. and G.P. performed experiments in cultured cells; S.S. performed Src kinase assays; M.P.R. performed the immunofluorescence analysis; P.F. and G.B. were involved in project planning and manuscript preparation. Competing interests: M.F., I.M., L.T., G.P., S.S., and P.F. are employees of Prassis sigma-tau Research Institute and G.B. is a paid consultant for Prassis sigma-tau. M.P.R. declares that she has no competing financial interests.